ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy
Released
Released
Announcement PDF
ASX Announcement
NEW PRECLINICAL DATA FOR AVICURSEN (ATL1102) SHOWS
POSITIVE SIGNALS OF ACTIVITY IN AUTOIMMUNE EPILEPSY
Melbourne, Australia – 3 September 2024: Percheron Therapeutics Limited (ASX: PER)
(‘the Company’), an international biotechnology company focused on the development
of novel therapies for rare diseases, is pleased to announce novel preclinical data for its
lead program, avicursen (ATL1102), in a mouse model of autoimmune epilepsy.
The data provides further validation for avicursen’s pharmacological activity as an antiinflammatory agent and suggests a new group of patients who may benefit from
avicursen in future.
Key Points
•
Epilepsy encompasses a diverse range of medical conditions characterized by
abnormal electrical activity in the brain causing seizures. It is estimated that 1 in 26
people suffer from epilepsy at some point in their lives. Autoimmune epilepsy is a
form of epilepsy caused by abnormal activity of the immune system within the brain.
It is estimated to represent 5-35% of all new cases of epilepsy. 1
•
Avicursen is an antisense oligonucleotide which targets CD49d, a cell surface
receptor implicated in the adhesion, migration, and activity of white blood cells. The
drug has previously shown evidence of activity in a diverse range of inflammatory
conditions, including positive clinical data in a phase II trial in multiple sclerosis and
a phase IIa trial in Duchenne muscular dystrophy (DMD). An international phase IIb
clinical trial in DMD is ongoing, with initial data expected in December 2024.
•
A murine analogue of avicursen in a mouse model of autoimmune epilepsy showed
a reduction in median seizure frequency of 66% for the drug when compared to a
saline control. The reduction was statistically significant.
“This is very encouraging new data,” commented Percheron CEO, Dr James Garner.
“Autoimmune epilepsy is a challenging disease with few treatment options, and a
substantial proportion of patients are children. We look forward to discussing these
results with clinicians and researchers over the coming months. This experiment has
been part of a focused effort to identify potential additive opportunities for avicursen,
with a view to expanding its use beyond DMD, and we are pleased to have seen a
positive signal. In the meantime, the results are also very helpful in a broader sense,
because they serve to further validate the pharmacological activity of avicursen and
expand our understanding of the drug.”
1
https://www.epilepsy.com/causes/autoimmune
Percheron Therapeutics Limited
ABN 41 095 060 745
ASX: PER | FSE: AWY | US OTC: ATHJY
Autoimmune Epilepsy
Autoimmune epilepsy was first systematically defined in 2017 and represents a
significant subset of patients with seizures. 2 Its causes and manifestations are diverse
but typically result in inflammation of the brain (encephalitis), and the condition is often
comparatively resistant to conventional anticonvulsant therapies. At present, treatment
is typically via corticosteroids, intravenous immunoglobulin, plasmapheresis, or other
immunosuppressive drugs, but a significant proportion of patients remain refractory and
there is an urgent need for new treatments.
Study Design
Avicursen was tested in a pilocarpine-induced seizure model, which is a wellestablished experimental system for investigating this family of disorders. 3 Forty mice
were divided into three groups, which received respectively (1) a single dose of a murine
analogue of avicursen; (2) a mismatch oligonucleotide control; and (3) a saline control,
once weekly for seven weeks.
The murine analogue of avicursen was used because of CD49d sequence differences
between humans and mice, which make it inappropriate to use an identical drug in both
species. The murine analogue was the same agent that has previously been used for
experiments in DMD and in limb girdle muscular dystrophy R2.
Outcome measures included the cumulative number of spontaneous recurring seizures
per hour and the duration of seizures. The study was conducted in a blinded fashion,
with observers unaware during assessment which mice had received which treatment.
The experiments were performed in a commercial contract research organisation under
the oversight of Percheron.
Preliminary Results
In animals who received the avicursen analogue, the median frequency of seizures was
0.0480 seizures per hour, compared to 0.1395 seizures per hour in the saline control,
representing approximately a 66% reduction, when measured from day 31 to day 43.
This result was statistically significant, with p < 0.05.
Similar treatment effects were observed when the active group was compared to a
negative control mismatch oligonucleotide, and in comparison to a pooled group of
saline and control oligonucleotide. No significant effect was seen in the duration or
severity of seizures.
2
3
https://practicalneurology.com/articles/2018-oct/autoimmune-epilepsy
PS Buckmaster & FH Lew (2011). J Neurosci. 31 (6) 2337-2347
Page 2 of 3
Next Steps
Although the in-life phase of the work is complete, histological assessment remains
ongoing to better understand the effects of avicursen on the activity of the immune
system in this disease model.
The company expects to share full data at a future academic conference. In the
meantime, customary measures have been taken to protect the novel intellectual
property resulting from this work.
As previously announced, avicursen is the subject of an ongoing international phase IIb
randomised controlled clinical trial in DMD, with initial data expected in December
2024.
~ ENDS ~
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed
biotechnology company focused on the development and commercialisation of novel therapies
for rare diseases. The company’s lead program is ATL1102, an antisense oligonucleotide
targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase
IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy
(DMD), for which data is expected in 2H CY2024. The company previously reported promising
results from an exploratory phase IIa study of in the same population and has been awarded
orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.
For more information, please contact info@PercheronTx.com.
This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.
Page 3 of 3
Share your feedback
Discover